Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy.
Schepisi G, Casadei C, Toma I, Poti G, Iaia ML, Farolfi A, Conteduca V, Lolli C, Ravaglia G, Brighi N, Altavilla A, Martinelli G, De Giorgi U. Schepisi G, et al. Among authors: iaia ml. Cancers (Basel). 2021 Feb 17;13(4):840. doi: 10.3390/cancers13040840. Cancers (Basel). 2021. PMID: 33671294 Free PMC article. Review.
Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients.
Puccini A, Ponzano M, Dalmasso B, Vanni I, Gandini A, Puglisi S, Borea R, Cremante M, Bruno W, Andreotti V, Allavena E, Martelli V, Catalano F, Grassi M, Iaia ML, Pirrone C, Pastorino A, Fornarini G, Sciallero S, Ghiorzo P, Pastorino L. Puccini A, et al. Among authors: iaia ml. Cancers (Basel). 2022 Sep 13;14(18):4447. doi: 10.3390/cancers14184447. Cancers (Basel). 2022. PMID: 36139606 Free PMC article.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Tailoring antiHer2 treatment strategies in breast cancer and beyond.
Fedele P, Sanna V, Santoro AN, Iaia ML, Fancellu A. Fedele P, et al. Among authors: iaia ml. Curr Probl Cancer. 2022 Oct;46(5):100892. doi: 10.1016/j.currproblcancer.2022.100892. Epub 2022 Aug 11. Curr Probl Cancer. 2022. PMID: 36055059 Review.
15 results